Combination of PIM and JAK2 inhibitors synergistically suppresses cell proliferation and overcomes drug resistance of myeloproliferative neoplasms

Inhibitors of JAK2 kinase are emerging as an important treatment modality for myeloproliferative neoplasms (MPN). However, similar to other kinase inhibitors, resistance to JAK2 inhibitors may eventually emerge through a variety of mechanisms. Effective drug combination is one way to enhance therape...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Shih-Min A., Wang, Anlai, Greco, Rita, Li, Zhifang, Sun, Fangxian, Barberis, Claude, Tabart, Michel, Patel, Vinod, Schio, Laurent, Hurley, Raelene, Chen, Bo, Cheng, Hong, Lengauer, Christoph, Pollard, Jack, Watters, James, Garcia-Echeverria, Carlos, Wiederschain, Dmitri, Adrian, Francisco, Zhang, JingXin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102815/
https://www.ncbi.nlm.nih.gov/pubmed/24830942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102815/
https://www.ncbi.nlm.nih.gov/pubmed/24830942

Ejemplares similares